PDF(Pubmed)
Abstract：
BACKGROUND: Subthalamic deep brain stimulation (STN-DBS) reduces antiparkinsonian medications in Parkinson\'s disease (PD) compared with the preoperative state. Longitudinal and comparative studies on this effect are lacking.
OBJECTIVE: To compare longitudinal trajectories of antiparkinsonian medication in STN-DBS treated patients to non-surgically treated control patients.
METHODS: We collected retrospective information on antiparkinsonian medication from PD patients that underwent subthalamic DBS between 1999 and 2010 and control PD patients similar in age at onset and baseline, sex-distribution, and comorbidities.
RESULTS: In 74 DBS patients levodopa-equivalent daily dose (LEDD) were reduced by 33.9-56.0% in relation to the preoperative baseline over the 14-year observational period. In 61 control patients LEDDs increased over approximately 10 years, causing a significant divergence between groups. The largest difference amongst single drug-classes was observed for dopamine agonists.
CONCLUSIONS: In PD patients, chronic STN-DBS was associated with a lower LEDD compared with control patients over 14 years.
OBJECTIVE: To compare longitudinal trajectories of antiparkinsonian medication in STN-DBS treated patients to non-surgically treated control patients.
METHODS: We collected retrospective information on antiparkinsonian medication from PD patients that underwent subthalamic DBS between 1999 and 2010 and control PD patients similar in age at onset and baseline, sex-distribution, and comorbidities.
RESULTS: In 74 DBS patients levodopa-equivalent daily dose (LEDD) were reduced by 33.9-56.0% in relation to the preoperative baseline over the 14-year observational period. In 61 control patients LEDDs increased over approximately 10 years, causing a significant divergence between groups. The largest difference amongst single drug-classes was observed for dopamine agonists.
CONCLUSIONS: In PD patients, chronic STN-DBS was associated with a lower LEDD compared with control patients over 14 years.
摘要：
背景：与术前状态相比，丘脑下深部脑刺激（STN-DBS）可减少帕金森病（PD）的抗帕金森病药物治疗。缺乏对这种影响的纵向和比较研究。
目的：比较STN-DBS治疗患者和非手术治疗对照组患者抗帕金森病药物的纵向轨迹。
方法：我们收集了1999年至2010年间接受丘脑下DBS治疗的PD患者和发病年龄和基线年龄相似的对照PD患者的抗帕金森病药物的回顾性信息。性别分布，和合并症。
结果：在74例DBS患者中，左旋多巴等效日剂量（LEDD）在14年的观察期内与术前基线相比减少了33.9-56.0％。在61名对照患者中，LEDDs在大约10年内增加，造成群体之间的显著分歧。观察到多巴胺激动剂在单一药物类别之间的最大差异。
结论：在PD患者中，与14年以上的对照组患者相比,慢性STN-DBS与较低的LEDD相关.
目的：比较STN-DBS治疗患者和非手术治疗对照组患者抗帕金森病药物的纵向轨迹。
方法：我们收集了1999年至2010年间接受丘脑下DBS治疗的PD患者和发病年龄和基线年龄相似的对照PD患者的抗帕金森病药物的回顾性信息。性别分布，和合并症。
结果：在74例DBS患者中，左旋多巴等效日剂量（LEDD）在14年的观察期内与术前基线相比减少了33.9-56.0％。在61名对照患者中，LEDDs在大约10年内增加，造成群体之间的显著分歧。观察到多巴胺激动剂在单一药物类别之间的最大差异。
结论：在PD患者中，与14年以上的对照组患者相比,慢性STN-DBS与较低的LEDD相关.
